诊断学理论与实践 ›› 2023, Vol. 22 ›› Issue (04): 379-384.doi: 10.16150/j.1671-2870.2023.04.008
姚勇1, 董争华2, 范厚臻3, 高云琴3, 刘谦3, 吴俊1()
收稿日期:
2023-06-10
出版日期:
2023-08-25
发布日期:
2023-12-18
通讯作者:
吴俊 E-mail:
YAO Yong1, DONG Zhenghua2, FAN Houzhen3, GAO Yunqin3, LIU Qian3, WU Jun1()
Received:
2023-06-10
Online:
2023-08-25
Published:
2023-12-18
摘要:
目的: 建立适合中国人群的凝血四项指标[活化部分凝血酶原时间(activated partial thromboplastin time, APTT)、凝血酶原时间(prothrombin time, PT)、凝血酶时间(thrombin time, TT)、纤维蛋白原(fibrinogen, FIB)]参考区间。方法: 收集来自上海市东方医院(南院)、北京积水潭医院、山东省临沂市中医医院共计668例中国健康成年人,采用cobas t 711平台检测其凝血四项指标,根据结果建立参考区间。结果: 适合中国人群的凝血四项指标参考区间为,APTT 26.6~43.6 s,PT 7.67~10.5 s,TT 14.5~19.2 s,FIB 193~419 mg/dL(1 L=10 dL)。凝血四项指标在不同性别、年龄和地区人群间均具有统计学差异,性别分析中,PT差异最为显著(P<0.001),PT和APTT中位数在男性人群中较高(P<0.01),FIB中位数在女性人群中较高(P=0.001)。以50岁分组,≤50岁人群与>50岁人群间的PT、TT中位数差异无统计学意义(P>0.05),>50岁人群的APTT、FIB中位数高于≤50岁人群(P<0.005);不同地区(上海、北京、山东)间APTT、FIB、PT、TT中位数差异有统计学意义(P<0.001),APTT和FIB中位数在上海地区最高,PT中位数在北京地区最高,TT中位数在山东地区最高。结论: 本研究建立了中国健康成年人群的凝血四项指标参考区间,而影响该参考区间的因素包括地区、年龄,而男、女间参考区间相近,提示实验室应根据自身情况及地区、年龄来建立适用的参考区间。
中图分类号:
姚勇, 董争华, 范厚臻, 高云琴, 刘谦, 吴俊. 中国健康成年人群凝血四项指标参考区间的建立与探讨[J]. 诊断学理论与实践, 2023, 22(04): 379-384.
YAO Yong, DONG Zhenghua, FAN Houzhen, GAO Yunqin, LIU Qian, WU Jun. Establishing reference intervals of four routine coagulation indicators in healthy Chinese adults[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(04): 379-384.
表2
入选中国健康成年人群中不同性别组凝血四项指标的比较
Gender | PT (s) | APTT (s) | TT (s) | FIB (mg/dL) |
---|---|---|---|---|
Male | ||||
Standard deviation | 9.3 (1.1) | 33.7 (4.7) | 16.4 (1.2) | 269.2 (58.7) |
Interquartile range | 9.3 (8.9-9.6) | 33.1 (30.8-36.2) | 16.2 (15.4-17.1) | 260.5 (231.7-293.0) |
Reference interval | 7.7-10.8 | 26.7-44.0 | 14.5-19.0 | 190.0-414.0 |
Female | ||||
Standard deviation | 9.1 (0.9) | 33.1 (4.3) | 16.5 (1.3) | 272.1 (42.3) |
Interquartile range | 9.1 (8.7-9.5) | 32.4 (29.9-35.4) | 16.2 (15.5-17.1) | 272.5 (242.2-309.0) |
Reference interval | 7.7-10.4 | 26.6-41.8 | 14.7-19.3 | 202.0-422.0 |
P | <0.001 | 0.048 | 0.029 | 0.001 |
Reference interval of healthy Chinese adults | 7.7-10.5 | 26.6-43.6 | 14.5-19.2 | 193.0-419.0 |
表3
入选中国健康成年人群中不同年龄组凝血四项指标的比较
Gender | PT (s) | APTT (s) | TT (s) | FIB (mg/dL) |
---|---|---|---|---|
Young group ≤50 (year) | ||||
Standard deviation | 9.2 (0.7) | 33.1 (4.0) | 16.3 (1.2) | 263.6 (52.2) |
Interquartile range | 9.2 (8.8-9.6) | 32.6 (30.3-34.8) | 16.2 (15.4-17.0) | 258.0 (231.0-285.0) |
Reference interval | 7.8-10.6 | 24.6-43.2 | 14.5-19.2 | 188.1-397.8 |
Elderly group >50 (year) | ||||
Standard deviation | 9.2 (1.5) | 34.0 (5.4) | 16.4 (1.3) | 298.2 (57.0) |
Interquartile range | 9.1 (8.7-9.5) | 33.3 (30.3-37.0) | 16.2 (15.4-17.2) | 289.5 (255.0-326.3) |
Reference interval | 7.3-10.8 | 26.7-44.3 | 14.5-19.5 | 212.9-443.4 |
P | 0.942 | 0.031 | 0.316 | <0.001 |
表4
来自不同地区三家中心的中国健康成人凝血四项指标参考区间(2.5%~97.5% CI)
Indice | Shanghai | Beijing | Shandong | P | Overall | Product Manual |
---|---|---|---|---|---|---|
APTT(s) | 34.1 (27.7-43.9) | 31.9 (25.9-39.1) | 32.1 (26.2-44.5) | <0.001 | 26.6-43.6 | 23.9-33.2 |
FIB(mg/dL) | 280.0 (206.0-397.0) | 245.0 (186.0-337.0) | 266.0 (203.0-461.0) | <0.001 | 193.0-419.0 | 193.0-412.0 |
PT(s) | 9.3 (8.35-10.4) | 9.3 (8.22-10.6) | 8.8 (7.29-10.5) | <0.001 | 7.67-10.5 | 8.4-10.6 |
TT(s) | 15.6 (14.5-17.1) | 16.2 (14.5-17.8) | 17.5 (14.6-19.8) | <0.001 | 14.5-19.2 | 16.1-19.7 |
[1] |
JI Q, XU Q, WANG Z, et al. Association between activated partial thromboplastin time, age and bleeding events in NVAF patients receiving dabigatran[J]. Eur J Clin Pharmacol, 2019, 75(3):321-328.
doi: 10.1007/s00228-018-2583-5 pmid: 30377709 |
[2] |
RUBERTO M F, MARONGIU F, SORBELLO O, et al. Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis?[J]. Int J Lab Hematol, 2019, 41(1):118-123.
doi: 10.1111/ijlh.12934 pmid: 30298976 |
[3] |
FAVALORO E J, LIPPI G. Understanding the extent of the diagnostic potential of coagulation factors[J]. Expert Rev Mol Diagn, 2020, 20(3):273-276.
doi: 10.1080/14737159.2020.1711735 pmid: 31903796 |
[4] | 王鹏辉. 血凝五项在常见肿瘤患者诊断中的临床应用[J]. 中外女性健康研究, 2019(9):124-125. |
WANG P H. Clinical application of coagulation routine 5 tests in the diagnosis of common tumor patients[J]. Women's Health Res, 2019(9): 124-125. | |
[5] | 谢红珍, 藤凯. 冠心病患者凝血和血小板状态的临床研究[J]. 江苏大学学报(医学版), 2004, 14(6):534-535. |
XIE H Z, TENG K. Clinical study on coagulation and platelet status in patients with coronary heart disease[J]. J Jiangsu Univ (Med), 2004, 14(6):534-535. | |
[6] | 邓顺顺, 张嘉萱, 朱涛, 等. 凝血功能检测对脑出血患者治疗情况评估的价值分析[J]. 哈尔滨医药, 2017, 37(3):256-257. |
DENG S S, ZHANG J X, ZHU T, et al. Analysis of the value of coagulation function testing in evaluating the treatment of patients with cerebral hemorrhage[J]. Harbin Med J, 2017(3):256-257. | |
[7] | 高爱平, 周金友, 张万翔. 五项凝血指标在不同程度肝病患者中结果观察与分析[J]. 中原医刊, 2003, 30(17):51. |
GAO A P, ZHOU J Y, ZHANG W X. Observation and analysis of the results of coagulation routine 5 assays in patients with different degrees of liver disease[J]. Cent Plains Med J, 2003(17):51. | |
[8] | 李清祥, 黄建华. 临床常见凝血指标异常结果分析[J]. 实验与检验医学, 2010, 28(2):173-174. |
LI Q X, HUANG J H. Analysis of abnormal results of common clinical coagulation assays[J]. Exp Lab Med, 2010, 28(2):173-174. | |
[9] | 张梦梦, 汤慧丽, 黄河, 等. 1 057例新生儿出生初期部分凝血功能检测指标危急值分析[J], 中华全科医学, 2023, 21(3): 361-364 |
ZHANG M M, TANG H L, HUANG H, et al. Analysis of the critical values of partial coagulation function indicators in 1 057 neonates in the early stages of life[J]. Chin J General Prac, 2023, 21(3): 361-364. | |
[10] | 陈丹, 陈丽萍, 包蕾. 中早期早产儿生后早期凝血功能异常的危险因素及结局分析[J]. 重庆医科大学学报, 2021, 46(9):1095-1099. |
CHEN D, CHENG LP, BAO L. Analysis of risk factors and outcomes for abnormal coagulation in early postnatal period in early and middle-term premature infants[J]. J Chongqing Med Univ, 2021, 46(9):1095-1099. | |
[11] |
ARAL H, USTA M, CILINGIRTURK A M, et al. Verifyi-ng reference intervals for coagulation tests by using stored data[J]. Scand J Clin Lab Invest, 2011, 71(8):647-652.
doi: 10.3109/00365513.2011.618546 URL |
[12] |
ZIERK J, GANSLANDT T, RAUH M, et al. Data mining of reference intervals for coagulation screening tests in adult patients[J]. Clin Chim Acta, 2019, 499:108-114.
doi: S0009-8981(19)32035-2 pmid: 31513787 |
[13] | 王薇, 钟堃, 何法霖, 等. 2012年全国凝血试验检验项目参考区间现状调查分析[J]. 中华血液学杂志, 2015, 36(1):39-43. |
WANG W, ZHONG K, HE F L, et al. The investigation of reference intervals application status of the analytes in coagulation test[J]. Chin J Hematol, 中华血液学杂志, 2015, 36(1):39-43. | |
[14] | SIVRIKAYA A, BARAN H, ABUSOGLU S, et al. Effect of gender and age on the prothrombin time (PT), activated partial thromboplastin time (aPTT) levels and international normalized ratio (INR)[J]. Int J Mevlana Med Sci, 2013, 1(2):27-29. |
[15] | 凝血因子活性测定技术标准[S]. WST220-2021. |
Technical standards for determination of coagulation factor activity[S]. WST220-2021. | |
[16] | 临床实验室检验项目参考区间的制定[S]. WST 402-2012. |
Establishment of reference intervals for clinical laboratory[S]. WST 402-2012. | |
[17] |
KITCHEN S, ADCOCK D M, DAUER R, et al. International Council for Standardization in Haematology (ICSH) recommendations for processing of blood samples for coa-gulation testing[J]. Int J Lab Hematol, 2021, 43(6):1272-1283.
doi: 10.1111/ijlh.v43.6 URL |
[18] |
OZARDA Y, HIGGINS V, ADELI K. Verification of refe-rence intervals in routine clinical laboratories: practical challenges and recommendations[J]. Clin Chem Lab Med, 2018, 57(1):30-37.
doi: 10.1515/cclm-2018-0059 URL |
[19] | ADCOCK D M, HOEFNER D M, KOTTKE-MARCHANT K, et al. CLSI Document H21-A5. Collection, Transport, and Processing of Blood Specimens for Testing plasma-based Coagulation Assays and Molecular Hemostasis Assays; Approved guideline[M]. 5th. Wayne, PA, USA: Clinical and Laboratory Standards Institute, 2008. |
[20] |
KITCHEN S, GEISEN U, KAPPELMAYER J, et al. Evaluating the analytical performance of four new coagulation assays for the measurement of fibrinogen, D-dimer and thrombin time. Int J Lab Hematol. 2018; 40(6):637-644.
doi: 10.1111/ijlh.12896 pmid: 30033683 |
[21] |
KITCHEN S, DE MAAT M, NAGLER M, et al. System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings[J]. Blood Coagul Fibrinolysis, 2020, 31(7):459-468.
doi: 10.1097/MBC.0000000000000947 URL |
[22] | OOSTENDORP M, NOORMAN R L, NIJENHUIS J D, et al. Performance of 6 routine coagulation assays on the new Roche Cobas t711 analyzer. Pract Lab Med. 2019, 17:e00146. |
[23] |
LIPPI G, SALVAGNO G L, GELATI M, et al. Analytical Assessment of the New Roche Cobas t 711 Fully Automated Coagulation Analyzer[J]. Semin Thromb Hemost, 2019, 45(3):308-314.
doi: 10.1055/s-0038-1676578 pmid: 30699441 |
[24] |
ZIERK J, GANSLANDT T, RAUH M, et al. Data mining of reference intervals for coagulation screening tests in adult patients[J]. Clin Chim Acta, 2019, 499:108-114.
doi: S0009-8981(19)32035-2 pmid: 31513787 |
[25] | ZHU C, SUN L, LI H, et al. Assessment and establishment of a reference interval for Roche Cobas t 711 coagulation analyzer for a hospital in China[J]. Pract Lab Med, 2022, 29:e00268. |
[1] | 杨文康, 张俊, 王淑秋, 祥巴央宗, 杨翠萍. 我国云南香格里拉地区104例肝硬化患者的病因及临床特征分析[J]. 诊断学理论与实践, 2022, 21(06): 730-734. |
[2] | 卢沭雄, 程凯, 采丽, 周晓蝶, 王建军, 王璇, 石群立. 性别决定区Y框蛋白在乳腺非特殊类型浸润性癌中的表达及临床病理意义[J]. 诊断学理论与实践, 2018, 17(06): 701-706. |
[3] | 堵一乔, 王文惠, 刘万超, 钮静, 史学娟, 杨振华. 血糖新评估指标1,5脱水山梨醇正常人群参考区间的建立[J]. 诊断学理论与实践, 2018, 17(02): 181-185. |
[4] | 许庆玲, 杨肖波, 吴超, 唐陈月, 俞丽芬,. 上海冠心病患者结肠直肠腺瘤患病率的横断面调查[J]. 诊断学理论与实践, 2016, 15(01): 47-52. |
[5] | 冯仁丰,. 关于实验诊断“参考区间”的问题[J]. 诊断学理论与实践, 2014, 13(02): 223-225. |
[6] | 张保平, 董莉, 冯新平, 萨仁娜, 王永祥,. 电化学发光免疫仪13项检测项目的生物参考区间在呼和浩特地区的验证分析[J]. 诊断学理论与实践, 2011, 10(05): 475-478. |
[7] | 李建新, 黄燕清, 聂李平, 周宇, 颜存粮, 任汉云,. 个体相关变量对中国健康人群常规凝血参数的影响[J]. 诊断学理论与实践, 2010, 9(01): 42-47. |
[8] | 王有菊, 史虹莉,. 年龄相关的睾酮水平改变[J]. 诊断学理论与实践, 2007, 6(05): 453-456. |
[9] | 史晓敏,徐国宾,夏铁安,王宏伟. 人血清N末端B型钠尿肽原参考值调查[J]. 诊断学理论与实践, 2005, 4(04): 291-295. |
[10] | 薛海波,张铁,肖世富,何燕玲,张明园. 影响老年成套神经心理测验的因素[J]. 诊断学理论与实践, 2004, 3(02): 40-42. |
[11] | 木村 聪,陈戈林,于颖彦. 特异性IgE抗体阳性率的大规模统计分析[J]. 诊断学理论与实践, 2002, 1(01): 46-47. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||